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Patients with high-risk endometrial carcinoma (stage IcG3, IIG3 with myometrial invasion 450%, and III) receive adjuvant therapy
after surgery but it is not clear whether radiotherapy (RT) or chemotherapy (CT) is better. We randomly assigned 345 patients with
high-risk endometrial carcinoma to adjuvant CT (cisplatin (50mgm
 2), doxorubicin (45mgm
 2), cyclophosphamide (600mgm
 2)
every 28 days for five cycles, or external RT (45–50Gy on a 5daysweek
 1 schedule). The primary end points were overall and
progression-free survival. After a median follow-up of 95.5 months women in the CT group as compared with the RT group, had a
no significant hazard ratio (HR) for death of 0.95 (95% confidence interval (CI), 0.66–1.36; P¼0.77) and a nonsignificant HR for
event of 0.88 (95% CI, 0.63–1.23; P¼0.45). The 3, 5 and 7-year overall survivals were 78, 69 and 62% in the RT group and 76, 66
and 62% in the CT group. The 3, 5 and 7-year progression-free survivals were, respectively, 69, 63 and 56 and 68, 63 and 60%.
Radiotherapy delayed local relapses and CT delayed metastases but these trends did not achieve statistical significance. Overall, both
treatments were well tolerated. This trial failed to show any improvement in survival of patients treated with CT or the standard
adjuvant radiation therapy. Randomised trials of pelvic RT combined with adjuvant cytotoxic therapy compared with RT alone are
eagerly awaited.
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Endometrial carcinoma is the most common cancer of the female
genital tract; it accounts for 7% of all cancers in women and has
an incidence of 20/100000womenyear
 1 in developed countries
(Pisani et al, 2002). The tumour is diagnosed in 75–80% of cases at
FIGO stage 1, which has 5-year survival rates of 80–90%. The
cornerstone of treatment is surgery (Look, 2002). In the early
stages, brachytherapy or external radiation therapy is advocated by
some as the optimal adjuvant treatment, although recent
randomised studies have shown that pelvic radiotherapy (RT)
improves loco regional control but not overall survival in patients
with low risk (Creutzberg et al, 2000) and intermediate risk
cancers (Keys et al, 2004). Adjuvant therapy is considered a
mainstay of management for advanced disease but the best therapy
to prevent recurrence is still controversial. Radiation therapy,
either external alone or combined with vaginal brachytherapy,
seems to lower the incidence of local recurrence, but has a
questionable role in preventing tumour spread, and distant
metastases remain a significant cause of failure in these patients.
Protocols for adjuvant systemic chemotherapies have therefore
been developed with a view to preventing distant recurrence.
Regimens active in advanced endometrial cancer usually include
a combination of an anthracycline compound and cisplatin, with
or without an alkylating agent. Cyclophosphamide, doxorubicin
(adriamycin) and cisplatin (CAP regimen) have given objective
responses in up to 76% of patients with advanced or recurrent
endometrial carcinoma (Turbow et al, 1985; Hancock et al, 1986;
Burke et al, 1991; Dunton et al, 1991) although the role of
cyclophosphamide in combination regimens remains controversial
(Thigpen et al, 1985).
The aim of this randomised study was to assess whether
adjuvant chemotherapy (CT) confers an advantage for overall and
progression-free survival and on the incidence of local and distant
relapses over standard pelvic RT, in high-risk patients without
residual tumour
PATIENTS AND METHODS
Eligibility and exclusion criteria
To be eligible for this study, patients had to have histologically
confirmed endometrioid, adenoacanthoma or adenosquamous
carcinoma and FIGO stage Ic G3, IIa-bG3 with deep myometrial
invasion (50% or more) or stage III disease. To rule out FIGO
stage IV disease all patients underwent chest radiography and
abdominal–pelvic ultrasound. Women had to have had surgery
as primary treatment and no previous neoadjuvant therapy
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sor adjuvant brachytherapy. Informed consent fulfilling the
requirements of local human biomedical ethics committees was
obtained from all patients before entry into the study.
Patients were excluded for any of the following criteria:
Karnofsky performance status less than 80; clear-cell, serous
papilliferous carcinoma or undifferentiated carcinoma; a second
malignant disease (with the exception of surgically treated in situ
carcinoma of the uterine cervix or basal cell carcinoma of the
skin); serious cardiopathy that would contraindicate the use of
adriamycin; inadequate liver or renal function (bilirubin levels
41.5mgdl
 1 or a serum creatinine 41.5mgdl
 1); inadequate
bone marrow function, defined as a leukocyte count o4 10
9l
 1
and/or platelet count o100 10
9l
 1; macroscopic residual
tumour.
Treatment schedules
All patients underwent surgery as primary treatment and with no
restrictions on the extent of primary surgery. The standard
surgical treatment was total abdominal hysterectomy with bilateral
salpingo-oophorectomy (TAH-BSO) with or without partial
colpectomy (excision of the vaginal cuff/upper third of vagina)
and selective pelvic and lumbo-aortic node sampling. The other
surgical procedures were vaginal hysterectomy with BSO, and
radical hysterectomy.
After surgical staging and histological evaluation the patients
were allocated to one of the two treatments, as follows:
Chemotherapy had to start within 30 days from surgery.
Cyclophosphamide 600mgm
 2, adriamycin 45mgm
 2 and cis-
platin 50mgm
 2 (CAP regimen) were administered every 28 days
for five cycles. In case of bone marrow suppression the doses were
adjusted following these criteria: leukocyte count 2.5–3.0 10
9l
 1
or platelet count o100 10
9l
 1 was managed by a 50% dose
reduction of cyclophosphamide and adriamycin; in case of
leukocyte count o2.5 10
9l
 1 the CT was interrupted until the
toxicity completely resolved. In case of severe nephrotoxicity,
defined as creatinine clearance p40mlmin
 1 per 1.73m
2,
cisplatin was interrupted and therapy continued with adriamycin
and cyclophosphamide only. For patients who experienced hepatic
dysfunction the protocol stipulated a 50% and a 75% reduction in
the adriamycin dosage if bilirubin was between 1.5 and 3mgdl
 1,
and if it was more than 3mgdl
 1.
Radiotherapy had to start within 30 days after surgery. External
radiation therapy was adopted for a total of 45–50Gy in 5–7
weeks (1.7–2Gyday
 1 5daysweek
 1). The upper limit of the
pelvic field was at L5, the lower limit at the lower limit of the
ischial tuberosity, and the lateral limits fell behind the border of
the lateral and common iliac lymph nodes. Patients who had
lymph node involvement received additional lumbo-aortic lymph





The patients were evaluated with periodic visits every 3 months in
the first 3 years, every 6 months in the next 2 years, then annually.
At each follow-up, symptoms were recorded, and abdominal
palpation and pelvic examination were performed. Vault smears
were taken every 6 months for the first 2 years, then annually.
Chest radiograms were taken once a year. Other diagnostic tests
were carried out whenever a recurrence was suspected. Any
complications were assessed at each visit. Chemotherapy toxicities
were graded according to World Health Organization criteria
(World Health Organization, 1979).
Statistical methods
The primary end points for this trial were overall survival, defined
as the time from randomisation to death, irrespective of the cause,
and progression-free survival, defined as the time from randomi-
sation to the earliest tumour relapse, or death. We calculated that a
total of 345 patients would permit the detection of a true 35%
relative decrease in the mortality hazard rate of patients in the CT
arm, with an 80% chance, when the type-I error is limited to 0.05
(two tails). Assuming, for example, a 5-year overall survival of 60%
for the RT group, a hazard ratio (HR) of 0.65 corresponds to an
absolute increase of 12% in 5-year overall survival.
Randomisation was carried out centrally by telephone at
the L Mangiagalli Institute (Milan, Italy) and patients were
stratified by institution and stage of disease. Overall and
progression-free survival curves were constructed with the
Kaplan–Meier method.
The cumulative incidences of local (central pelvic, including
vaginal cuff recurrence, lateral pelvic and vaginal) and distant
relapses at a time point were calculated using the Kaplan–Meier
approach accounting for the presence of competing risk events.
Competing risk events were considered distant relapse or death
without relapse when calculating the cumulative incidence of local
relapse and local relapse or death without relapse when calculating
the cumulative incidence of distant relapse (Satagopan et al, 2004).
We considered the incidence of local and distant relapses as first
failure only. If local and distant relapses were detected concur-
rently these cases were shown on the cumulative incidence curves
of both local and distant relapses.
The duration of follow-up was calculated using the Kaplan–
Meier estimate of the median duration by reversing the status
of censoring and death in the data set. The log-rank test and
Cox proportional hazards regression models were used to compare
time-to-event distributions between the treatment groups in
univariate and multivariate analyses. The 95% CIs for the HRs of
treatment effect and other prognostic factors were provided to
indicate the range of values consistent with the observed data and
were determined from the asymptotic s.e. in the Cox regression
model. All statistical tests were two-sided. The analysis was by
intention-to-treat and patients were analysed according to the
assigned treatment.
The results are reported according to the revised CONSORT
statement (Moher et al, 2001).
RESULTS
Patients characteristics and compliance with treatment
Between January 1, 1990 and December 31, 1997, 491 patients with
high-risk endometrial carcinoma were consecutively referred to 29
institutions throughout Italy. A total of 345 patients were deemed
eligible for this study, with 168 randomly assigned external RT and
177 adjuvant CT (Figure 1).
Table 1 lists the distribution by treatment group of patients
according to age, FIGO stage, grading, degree of myometrial
invasion and type of primary surgery. The two groups were similar
across all categories. About one third of the patients had FIGO
stage I–II disease and two thirds stage III, and approximately 70%
of the patients had myometrial invasion deeper than 50%. Of the
340 patients analysed, 315 (93%) underwent TAH-BSO.
Of the 166 patients assigned RT, 146 (88%) completed treatment
as planned (Figure 1); only four patients (2%) stopped treatment
because of toxicity (investigators were not required to report
the specific toxic effect that prompted treatment cessation); 10
patients (6%) declined treatment. Of the 174 patients assigned
CT, 131 (75%) received five treatment cycles as planned and
154 (89%) received at least one cycle and were assessable for
toxicity (six, four, four and nine patients received only one, two,
three and four courses of CAP, respectively, mainly because of
excessive bone marrow toxicity). In all, 12 patients (7%) declined
adjuvant CT.
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We had toxicity data for 146 (97%) of the 150 patients who started
RT (RT). Major late toxic effects were gastrointestinal, including
five cases of bowel obstruction with three of these patients
requiring surgical intervention, six cases of grade 3 radiation
proctitis, and 13 reports of grade 3 diarrhoea (24 patients, 16%).
Urinary tract complications (severe actinic cystitis) were recorded
in seven patients (5%).
We collected full details about the toxicity of CAP for 123
patients (80% of the 154 patients who had at least one course).
Grades 2, 3 and 4 neutropenia occurred in 22 (18%), 38 (31%)
and 5 (4%) patients, respectively; 36 patients (29%) had grade 2
anaemia, 5 (4%) had grade 3 anaemia; grade 2 and 3
thrombocytopenia was reported in five (4%) and two patients
(2%), respectively. The incidence of nausea and vomiting was
relatively low (grade 2 and 3 was reported for 29 (24%) and 12
(10%) patients, respectively, grade 4 for one patient). Other serious
toxicities (grade 3) occurred in o3 % of the patients randomised
to CT. There were no treatment-related deaths.
Recurrence and survival
At the median follow-up time of 95.5 months (interquartile range
62 to 122 months), 135 events (recurrences or deaths, whichever
came first) had occurred among the 340 randomised patients: 60
recurrences and nine deaths as first event of the 166 patients on
RT, and 56 recurrences and 10 deaths as first event of the 174
patients on CT. The overall number of observed deaths was 118
(35%), 59 in the RT arm and 59 in the CT arm. Comparison of the
Kaplan–Meier curves for death (Figure 2) or first event (Figure 3)
gave nonsignificant HRs of 0.95 (CI¼0.66–1.36, P¼0.78) and 0.88
(CI¼0.63–1.23, P¼0.45), respectively (Figure 2).
The overall survival of the patients on CT was 76% (CI¼70–
83%), 66% (CI¼59–73%) and 62% (CI¼55–70%) at the third,
fifth and seventh year, respectively, and 78% (CI¼71–84%), 69%
(CI¼61–76%) and 62% (CI¼54–71%) for patients on RT at the
same time points. The progression-free survival of the patients
on CT was 68% (CI¼61–75%), 63% (CI¼55–70%) and 60%
(CI¼52–67%) at the third, fifth and seventh year, respectively,
and 69% (CI¼62–77%), 63% (CI¼55–70%) and 56% (CI¼46–
63%) for patients on RT.
In the multivariate proportional hazard model (Table 2) age,
grading, depth of myometrial invasion and FIGO stage were all
significantly associated with progression-free and overall survival.
Randomised patients
(n = 345)  
Patients allocated to RT
(n = 168)  
Patients allocated to CT
(n = 177) 
166 Analysed    174 Analysed 
Patients not eligible
because of lower risk
profile (n = 2)∗ 
Patients not eligible
because of lower risk




6 Not evaluable for




8 Not evaluable for
therapy    
Figure 1 Flow chart of the progress of patients through the trial
(Adapted from Begg C, Cho M, Eastwood S, et al. proving the quality of
reporting of randomised controlled trials: the CONSORT statement. JAMA
1996;276;637–639). * Lower risk profile¼FIGO stage IaG1-3, IbG1-3,
IcG1-2, IIaG1-2, IIbG1-2.





No. % No. %
Median age (25th–75th percentiles), years 62 (55–67) 63 (57–69)
FIGO stage
Ic 43 26 47 27
I I a 21 00
IIb 15 9 14 8
IIIa 64 39 73 42
IIIb 5 3 2 1
IIIc 37 22 38 22
Histological grade
1 1 9 1 21 38
24 3 2 6 5 9 3 4
39 8 5 9 9 4 5 4
Missing data 6 4 8 5
Myometrial invasion
M0 (no invasion) 1 1 0 0
M1 (invasionp50%) 37 22 42 24
M2 (invasion 450%) 118 71 125 72





108 65 110 63




Vaginal hysterectomy-BSO 1 1 2 1
MEIGS radical hysterectomy 5 3 2 1
Missing data 4 2 7 4
Note: Clinical stage based on the International Federation of Gynecology and







166 151 129 109 100 88 77 68 51 42 27































012 45 89 1 0 36 7
Figure 2 Overall survival of patients with high-risk endometrial
carcinoma (stage IcG3, IIG3 with myometrial invasion 450%, and III)
receiving adjuvant radiotherapy (Radio) or chemotherapy (Chemio). Five-
year overall survival was 69% and 66% respectively for adjuvant
radiotherapy and chemotherapy.
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sMultivariate analysis confirmed there was no real difference
between CT and RT in progression-free and overall survival.
Figures 4 and 5 depict the cumulative incidence, after adjusting
for competing risks, of distant or local relapses by treatment arm.
Among the 166 patients randomised to RT, the initial site of
recurrence was distant (extra-abdominal or liver) in 35 (21%),
local in 11 (7%), concurrent distant and local in nine (5%), and of
unknown type in five (3%). Among the 174 patients randomised to
CT, the initial site of recurrence was distant in 27 (16%), local in 19
(11%), concurrent local and distant in eight (5%), and of unknown
type in two (1%). Although this study was not powered to detect
clinically significant differences in the incidence of relapses, CT
seemed to prevent or delay distance relapses more than RT
(Figure 4) while the RT seemed to prevent or delay local relapses in
comparison with CT (Figure 5).
DISCUSSION
To our knowledge, this was the first trial to randomise patients
with high-risk endometrial cancer to compare the efficacy of
adjuvant CT and standard pelvic RT. This trial failed to show an
improvement in progression-free and overall survival in patients
treated with one or the other treatment protocol. Both therapeutic
approaches were associated with acceptable toxicities.
Optimal adjuvant therapy for patients with high-risk disease
is poorly defined. Three randomised clinical trials comparing
adjuvant pelvic RT with brachytherapy (Aalders et al, 1980) or
observation (Creutzberg et al, 2000; Keys et al, 2004) all showed a
highly significant reduction of the risk of loco regional relapse with
pelvic irradiation but no clear trend toward prevention of distant
metastases or improvement of overall survival (Creutzberg, 2004).
Evidence on the effects of platinum-based systemic CT in an
adjuvant setting for endometrial cancer come from prospective
nonrandomised small series of patients. Therefore, comparisons of
adjuvant CT with adjuvant radiation were largely indirect and
tended to favour CT (Aoki et al, 2001, 2004) although it was clear
that CT did not prevent loco-regional recurrences. Our trial
directly compared adjuvant pelvic RT and CT, with an experi-
mental design similar to the GOG-122 trial that has been recently
published (Randall et al, 2006). The GOG study randomised
women with stage III–IV endometrial carcinoma to whole
abdominal irradiation or platinum-doxorubicin CT and reported
a clear benefit of combined cytotoxic therapy in terms of
progression-free survival and overall survival. The HRs of
progressing and dying relative to RT adjusted for stage were 0.71
(95% CI¼0.55–0.91) and 0.68 (95% CI¼0.52–0.89), respectively.
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Figure 3 Progression-free survival of patients with high-risk endometrial
carcinoma (stage IcG3, IIG3 with myometrial invasion 450%, and III)
receiving adjuvant radiotherapy (Radio) or chemotherapy (Chemio). Five-
year progression-free survival was 63% and 63%.
Table 2 Multivariable Cox proportional hazards analysis for progression-
free and overall survival
Progression-free survival Overall survival
HR (95%CI) P HR (95%CI) P
Treatment arm
Radiotherapy
a 1 0.64 1 0.85
Chemotherapy 0.92 (0.65–1.30) 1.04 (0.72–1.50)
Age (years)
o70
a 1 0.009 1 0.001
X70 1.71 (1.15–2.56) 1.99 (1.31–3.02)
Tumor grade
1o r2
a 1 o0.0001 1 o0.0001
3 2.74 (1.78–4.22) 3.09 (1.96–4.89)
Myometrial invasion
p50%
a 1 0.001 1 0.002
450% 2.20 (1.36–3.57) 2.22 (1.34–3.69)
Stage
Io rI I
a 1 o0.0001 1 o0.0001
III 2.70 (1.75–4.15) 3.17 (2.00–5.01)




























Figure 4 Cumulative incidence of distant relapses for patients with high-
risk endometrial carcinoma (stage IcG3, IIG3 with myometrial invasion




























Figure 5 Cumulative incidence of local (central pelvic, including vaginal
cuff recurrence, lateral pelvic and vaginal) relapses for patients with high-risk
endometrial carcinoma (stage IcG3, IIG3 with myometrial invasion 450%,
and III) receiving adjuvant radiotherapy (Radio) or chemotherapy (Chemo).
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sdifferences between the two studies that need comment: in the
GOG trial a sizeable proportion of patients (about 25%) were
reported as having other and more aggressive pathologic types
than endometroid or adenosquamous (ie serous and clear-cell) and
included stage IV disease and patients with residual tumour up to
2cm, so the study population had a much higher risk of relapse
and death (5-year overall survival was 42% in the RT arm, 53%
in the CT arm); the CT regimen was a doublet (doxorubicin and
cisplatin) not the triplet used in our study (doxorubicin, cisplatin
and cyclophosphamide); the doxorubicin dose in the GOG proto-
col was higher and CT was cycled every 3 weeks instead of 4 weeks
for seven courses with an additional course of cisplatin, instead of
five courses; RT was whole abdominal irradiation with a boost to
pelvis, not just limited to the pelvis as in our study; in the GOG
trial there were 12 treatment-related deaths (four RT, eight CT).
We thought that the differences between our study and GOG-122
might have been related to differences in histological subtypes,
which were more aggressive and possibly more chemoresponsives
in the GOG-122 population but a recent pooled analysis of four
GOG studies showed similar response rates of endometroid and
serous tumours to CT (Scott et al, 2005). Thus, differences can only
be explained with the combination of the more aggressive GOG-
122 CT schedule and a target patient population with poorer
prognosis.
When our study was designed, the drug combination proposed
in the protocol (the CAP regimen, cycled every 4 weeks) was
considered effective in advanced endometrial and ovarian cancer
(de Oliveira et al, 1990; Burke et al, 1991). The CAP regimen,
although usually cycled every 3 weeks, is still widely used and
many clinicians in Europe use it as first-line treatment for ovarian
cancer (International, 2002). The doxorubicin dose in the CAP
regimen is lower than the dose used in the GOG-122 trial but a
recent retrospective analysis of three phase III trials in 630 patients
indicated that the risk of cardiotoxicity (ie irreversible cardiac
heart failure) began to increase with cumulative doses of
conventional doxorubicin as low as 300mgm
 2 (Swain et al,
2003). The GOG-122 maximum allowable cumulative dose of
doxorubicin was 420mgm
 2 and this should set the estimated risk
range of cardiomyopathy between 5 and 16%.
The cumulative incidence curves of local and distant relapses
in our study suggest that RT might achieve better loco-regional
control while systemic CT might control distant metastases better.
Although both approaches are still unsatisfactory, since the risk
of progression or death remains high, this encouraging evidence
of clinical activity suggest they might be used concurrently or
sequentially use in an adjuvant setting. Only one randomised trial
assessed the efficacy of adjuvant CT after RT compared with RT
alone (Morrow et al, 1990). This GOG trial randomised high-risk
patients to receive doxorubicin or no further therapy after
postoperative pelvic RT. No differences emerged in overall survival
but the trial was probably underpowered to detect a clinically
important effect.
In an attempt to maximise treatment activity several cooperative
groups have launched randomised trials comparing RT plus CT
with RT alone in high-risk endometrial cancer (ILIADE group,
EORTC 55991). These will further define the optimal sequencing of
treatment approaches including concomitant RT and CT that
showed acceptable safety and toxicity in preliminary analyses
(Greven et al, 2004).
In this setting, taxane-platin combinations seem promising
especially, considering the possible role of taxane compounds as
radiation enhancer (Liebmann et al, 1994a,b).
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